Alzheimer's Disease and Dementia
Our work in Alzheimer's Disease and Dementia
-
New USC Study Finds People of Color Live More Years with Dementia Diagnosis Than Non-Hispanic Whites
These findings further reinforce the need for targeted support and resources for families and patients living with Alzheimer’s and other dementias.
-
Aduhelm Decision Shows Medicare is Making a Mistake in the Fight Against Alzheimer’s
The medical need is too great that the FDA should not limit targeted therapies and diagnostics.
Categorized in -
Racial and Ethnic Differences in Risk and Protective Factors of Dementia and CIND in the United States
Recent population-based studies have shown declines in dementia prevalence in high-income countries, suggesting that improved population cardiovascular health and rising levels of education in the past 25 year were associated with reduction of dementia risks.
-
Racial/Ethnic Disparities in Length of Life after Dementia Diagnosis: an 18-Year Follow-up Study of Medicare Beneficiaries
Quantifying survival time after dementia diagnosis and assessing mechanisms driving differences across race/ethnicity to inform care and financial planning.
-
Cognitive Decline at Middle Age
Schaeffer Center researchers quantified the population with fast rates of cognitive decline at middle age, explored the distribution of cognitive trajectories, and investigated demographic, health, and socioeconomic factors associated with cognitive deterioration for Americans.
-
Pilot Funding Available for Researchers of Alzheimer’s, Aging
Pilot funding amounts range from $25,000 to up to $45,000. An informational session on the application process will be held over zoom on Thursday, December 9, 2021, at 10:00 a.m. pacific.
-
Schaeffer Center P30 Pilots Info Session
Join Schaeffer Center for a joint info session on pilot opportunities ($25K-$45K) through our NIH-funded P30 centers.
-
Sex Differences in the Association Between Metabolic Dysregulation and Cognitive Aging: The Health and Retirement Study
Dysregulation of some metabolic factors increases the risk of dementia. It remains unclear if overall metabolic dysregulation, or only certain components, contribute to cognitive aging and if these associations are sex specific.
Categorized in -
The Costs of Developing Treatments for Alzheimer’s Disease: A Retrospective Exploration
In over 26 years of research and development in Alzheimer’s disease, only six novel drugs have reached FDA approval.
Categorized in -
NAM Expert Briefing on Social Science Research Questions Raised By the Use of Biomarkers for Alzheimer’s Disease Diagnostics
On June 28 and 29, 2021, the National Academies of Sciences, Engineering, and Medicine convened an expert meeting that addressed behavioral and social science research questions raised by the use of biomarkers and other measures for pre-clinical AD/ADRD diagnosis